“Shift Toward Fish Oil-Based Lipid Emulsions and Personalized Nutrition Strategies to Mitigate PNAC Risk”
- One prominent trend in Parenteral Nutrition-Associated Cholestasis (PNAC) Treatment is the shift toward fish oil-based lipid emulsions and personalized nutrition strategies
- This shift is driven by increasing clinical evidence linking traditional soybean oil-based lipid emulsions to the development of PNAC in neonates and critically ill patients. Fish oil-based alternatives, rich in omega-3 fatty acids, have demonstrated anti-inflammatory properties and a lower incidence of liver complications
- For instance, healthcare providers are increasingly adopting products like Omegaven by Fresenius Kabi, a fish oil-based intravenous lipid emulsion, which has shown effectiveness in reducing cholestasis in pediatric patients on long-term parenteral nutrition
- This trend is significantly transforming the clinical management of PNAC by reducing liver-related complications, improving patient outcomes, and supporting a more tailored approach to nutrition therapy based on individual metabolic needs and risk profiles
- The PNAC Treatment market is poised for long-term growth, fueled by rising demand for safer lipid alternatives, advancements in nutritional science, and a broader move toward evidence-based, personalized medical nutrition strategies in neonatal and critical care settings
